A Phase 2 Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of BHV-4157 in Patients With Mild to Moderate Alzheimer's Disease
Status: Active, no longer recruiting
Phase of Trial: Phase II/III
Latest Information Update: 08 Nov 2019
Price : $35 *
At a glance
- Drugs Troriluzole (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Acronyms T2 Protect AD
- Sponsors Biohaven Pharmaceutical; Biohaven Pharmaceutical Holding Company
- 05 Nov 2019 According to a Biohaven Pharmaceutical media release, an interim futility analysis results expected in the fourth quarter of 2019 (end of this year).
- 05 Nov 2019 Status changed from recruiting to active, no longer recruiting.
- 25 Oct 2019 Planned number of patients changed from 292 to 336.